Alphabet's venture division GV (Google Ventures) led a $135M Series B funding round into genomic medicine startup Chroma Medicine.
Incoming funds will enable the firm to advance its therapeutic programs toward clinical trials as it strives to become a leader in epigenetic editing therapeutics.
- The Cambridge, Massachusetts-based startup emerged from stealth in November 2021 with a $125M Series A funding round.
- Since then, the company has worked on developing promising proof-of-concept data and narrowed its scope to a few diseases.
- The fresh funding will give the firm enough cash runway to progress toward clinical trials and develop new therapeutics.
- New investors ARCH Ventures Partners, DCVC Bio, Mubadala Capital, and Sixth Street participated in the funding round, joined by existing backers Atlas Venture, Omega Funds, T Rowe Price, Sofinnova Partners, and others.
